Series C Funding Round Attracts $110M for Capstan Medical

Capstan Medical has closed an oversubscribed $110 million Series C financing round led by Eclipse, with participation from existing investors Yu Galaxy and Intuitive Ventures, and new investment from Gideon Strategic Partners.

Heart disease remains the leading cause of death worldwide, claiming a life every 33 seconds in the United States alone. There currently are more than 7 million people in the United States with heart valve disease, a complex condition made up primarily of dysfunctional mitral and tricuspid valves. Current treatment options, typically by open heart surgery, are not viable for most patients and existing catheter-based options have high rates of patient exclusion. Capstan’s minimally invasive solution seeks to overcome limitations of current treatment options by bringing together novel heart valve implants and advanced catheter technology, fully enabled through a robotic platform, to treat a broader set of patients.

“Percutaneous intervention has the opportunity to dramatically increase the treatment options for the millions of people suffering from heart valve disease. At Capstan, we believe that our robotic platform with a full portfolio of implants can uniquely address the urgent needs of this underserved patient population,” Capstan Medical CEO Maggie Nixon said. “We have pulled together the right people at the right time to make this happen and are energized by the support of our investors.”

Since its founding in 2020, Capstan Medical has built a team with heart valve, implant delivery, and robotics expertise, growing to more than 75 employees across engineering, operations, clinical, and regulatory. With this new funding, the team will continue to execute on its plan for expanded clinical and development work leading to upcoming pivotal trials.

“We’re at an inflection point where robotics will play a consequential role in delivering life-saving solutions to millions of patients across the world,” Eclipse Partner Justin Butler stated. “Capstan is at the forefront of this wave with their robotic solutions for structural heart disease.”

Founded in 2020, Capstan Medical aims to create a new standard for minimally invasive heart valve intervention. The company is developing next-generation heart valve implants and a first-of-its-kind catheter-based robotic delivery platform.